title: Current update on eosinophilic lung diseases and anti-IL-5 treatment.
abstract: Peripheral blood eosinophilia and eosinophilic lung inflammation are common in a variety of pulmonary conditions, including eosinophilic pneumonia and asthma, hypereosinophilic syndrome and Churg-Strauss syndrome. Therapy in most of these clinical entities consists of long-term treatment with systemic corticosteroids, which is not always successful and has substantial side-effects. Interest has increased considerably regarding alternative corticosteroid-sparing "smart" regimens in these diseases that target IL-5, an important regulator of eosinophilic development and function. To date, two humanized monoclonal antibodies, mepolizumab and reslizumab, have been developed that bind to human IL-5. In addition a new monoclonal antibody (MEDI-563) has been recently developed targeting the IL-5 receptor. This review will investigate the current status on IL-5 targeted therapy and related patents regarding eosinophil-driven respiratory diseases, primarily eosinophilic asthma but also CSS and HES. Recent advances and information from clinical trials will be presented in a way that will allow the reader to approach the role of the eosinophil in the lung diseases presented in this review.
authors.affiliation: 7th Respiratory Department and Asthma Centre, Athens Chest Hospital, Athens, Greece.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Samitas
authors.forename: Madeleine
authors.initials: M
authors.lastname: Rådinger
authors.forename: Apostolos
authors.initials: A
authors.lastname: Bossios
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D015267:Churg-Strauss Syndrome / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D016503:Drug Delivery Systems / Q000639:trends*; D004802:Eosinophilia / Q000188:drug therapy* / Q000276:immunology; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology; D006801:Humans; D015848:Interleukin-5 / Q000037:antagonists & inhibitors* / Q000276:immunology*; D008171:Lung Diseases / Q000188:drug therapy* / Q000276:immunology; D011657:Pulmonary Eosinophilia / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015848:Interleukin-5; C434107:mepolizumab